NasdaqCM - Nasdaq Real Time Price
USD
Nektar Therapeutics (NKTR)
65.70
+4.72
(+7.74%)
At close: 4:00:00 PM EDT
65.50
-0.20
(-0.30%)
After hours: 6:19:11 PM EDT
Trade NKTR on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for NKTR
- Previous Close
60.98 - Open
62.30 - Bid 56.38 x 100
- Ask 74.67 x 100
- Day's Range
62.30 - 66.60 - 52 Week Range
8.35 - 109.00 - Volume
1,296,539 - Avg. Volume
1,012,733 - Market Cap 2.06B
- Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-7.93 - Earnings Date (est.) Aug 6, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
153.25
Recent News
View More
Performance Overview
Trailing total returns as of 6/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
NKTR
55.39%
S&P 500 (^GSPC)
9.16%
1-Year Return
NKTR
672.03%
S&P 500 (^GSPC)
25.22%
3-Year Return
NKTR
696.36%
S&P 500 (^GSPC)
70.54%
5-Year Return
NKTR
73.73%
S&P 500 (^GSPC)
75.98%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/18/2026
-
Market Cap
2.06B
-
Enterprise Value
1.57B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
21.42
-
Price/Book (mrq)
3.58
-
Enterprise Value/Revenue
28.31
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-284.18%
-
Return on Assets (ttm)
-15.29%
-
Return on Equity (ttm)
-53.60%
-
Revenue (ttm)
55.63M
-
Net Income Avi to Common (ttm)
-158.1M
-
Diluted EPS (ttm)
-7.93
Balance Sheet and Cash Flow
-
Total Cash (mrq)
568.6M
-
Total Debt/Equity (mrq)
24.89%
-
Levered Free Cash Flow (ttm)
-107.23M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Lowering target price to $0.58
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.584000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target -
Lowering target price to $0.63
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.632000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice Target -
Lowering target price to $0.93
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.928000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target -
What does Argus have to say about NKTR?
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $1.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target
